WO2020096299A1 - Extrait de thé vert ayant une teneur en constituants modifiée et composition le comprenant - Google Patents

Extrait de thé vert ayant une teneur en constituants modifiée et composition le comprenant Download PDF

Info

Publication number
WO2020096299A1
WO2020096299A1 PCT/KR2019/014810 KR2019014810W WO2020096299A1 WO 2020096299 A1 WO2020096299 A1 WO 2020096299A1 KR 2019014810 W KR2019014810 W KR 2019014810W WO 2020096299 A1 WO2020096299 A1 WO 2020096299A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition
green tea
weight
extract
tea extract
Prior art date
Application number
PCT/KR2019/014810
Other languages
English (en)
Korean (ko)
Inventor
김아영
김형수
박원석
조시영
홍용덕
권구상
Original Assignee
(주)아모레퍼시픽
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020190037810A external-priority patent/KR20200051452A/ko
Application filed by (주)아모레퍼시픽 filed Critical (주)아모레퍼시픽
Priority to CN201980073102.7A priority Critical patent/CN112996526B/zh
Priority to EP19881736.3A priority patent/EP3878460A4/fr
Publication of WO2020096299A1 publication Critical patent/WO2020096299A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L5/00—Preparation or treatment of foods or foodstuffs, in general; Food or foodstuffs obtained thereby; Materials therefor
    • A23L5/20—Removal of unwanted matter, e.g. deodorisation or detoxification
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/82—Theaceae (Tea family), e.g. camellia

Definitions

  • the present invention is a green tea extract with a changed component content, comprising a green tea extract with reduced hepatotoxicity, and an active ingredient thereof, for improving blood circulation, for suppressing fat accumulation in hepatocytes, for inhibiting ginger ballis bacteria, or for increasing cerebral blood flow. It is about.
  • Fatty liver is the main cause of chronic drinking, overeating and diabetes due to overeating, and other toxic drugs, antibiotics taken incorrectly during pregnancy, and fever-infected infections in children. As a result, fatty liver may occur even if aspirin is abused.
  • fatty livers are easily recovered by regeneration of hepatocytes when physical requirements such as immune status are good, but otherwise, as fat accumulates in the hepatocytes, important components of cells, including the nucleus, are pushed to one side, and the function of hepatocytes decreases, accumulating in the cells Due to the fat, the expanded hepatocytes press the microvascular and lymph glands between the hepatocytes, causing disorders in the circulation of blood and lymphatic fluid in the liver, and the liver cells are unable to receive oxygen and nutrients properly, resulting in deterioration of liver function.
  • the blood circulation disease maintains homeostasis by balancing the activation and suppression reactions of the hemostatic mechanism in normal blood vessels, and excessive hemostatic action or formation of blood clots interferes with the flow of blood flow, thereby causing thrombus.
  • Normal vascular endothelial cells act to inhibit the adhesion and activation of platelets by protecting the blood vessel walls by releasing inhibitors such as nitrogen monoxide (NO) and prostacyclin (PGI2), but when endothelial cells are damaged, platelets Coagulation is promoted.
  • NO nitrogen monoxide
  • PKI2 prostacyclin
  • the thrombosis is a disease that occurs when blood clots block blood vessels.
  • Periodontitis has a complex onset and variable symptoms.
  • One of the main causes of periodontitis is due to microorganisms in the oral cavity. They primarily produce insoluble glucan using sugars and the like, and they attach to the tooth surface like various cells to form tartar. Dental cavities and periodontitis are caused by these calculus. Therefore, the most effective way to prevent periodontitis can be achieved by using substances that inhibit the activity of these microorganisms and improve the blood flow in the gums where inflammation has occurred.
  • Microorganisms distributed in the oral cavity cause periodontal disease, periodontal disease, etc., and some of these microorganisms are known to have the possibility of disease development as opportunistic pathogens.
  • Several species are known as pathogenic microorganisms that cause periodontitis in the oral cavity, but among them, Prevotella intermedia and Porphyromonas gingivalis are known to be the main pathogens that cause periodontitis. have.
  • the brain performs its functions by receiving blood ejected from the heart and obtaining nutrients such as oxygen and glucose.
  • the brain has little ability to accumulate oxygen and glucose in the tissues. Therefore, when the blood vessels supplied to the brain become obstructed by the narrowing or closing of blood vessels by arteriosclerosis or blood clots, oxygen deficiency and glucose
  • the lack of causes brain disease, including damage to nerve cells.
  • Diseases that are directly or indirectly associated with disorders of cerebral blood flow include anemia, stroke, vascular dementia, Parkinson's syndrome, and Huntington's disease.
  • green tea has a weight-loss and cholesterol-lowering effect, and is widely used as a supplement to improve obesity or metabolic diseases.
  • ingesting a large amount of green tea extract may damage the liver, and safety issues for green tea extract have emerged. Therefore, there is a need to discover the composition of green tea extract that reduces liver damage in green tea.
  • the present invention is a hepatotoxicity caused by green tea, specifically, green tea extract in which hepatic cell damage is alleviated, and high safety, including it as an active ingredient, improves blood circulation, inhibits fat accumulation in hepatocytes, inhibits ginger ballis bacteria, or increases brain blood flow It is an object to provide this excellent composition.
  • the present invention in one aspect, based on the total weight of the extract, comprising 8% by weight or less of epigallocatechin (EGC), provides a green tea extract with reduced hepatotoxicity.
  • ECG epigallocatechin
  • based on the total weight of the extract comprising a green tea extract with less than 8% by weight epigallocatechin (EGC), hepatotoxicity is reduced, as an active ingredient, provides a composition for improving blood circulation .
  • ELC epigallocatechin
  • the present invention based on the total weight of the extract, containing less than 8% by weight of epigallocatechin (epigallocatechin, EGC), containing the green tea extract with reduced liver toxicity as an active ingredient, fat accumulation in liver cells Provided is a composition for inhibition.
  • epigallocatechin epigallocatechin, EGC
  • the present invention based on the total weight of the extract, containing less than 8% by weight of epigallocatechin (epigallocatechin, EGC), containing the green tea extract with reduced hepatotoxicity as an active ingredient, inhibiting ginger germs
  • EGC epigallocatechin
  • the present invention based on the total weight of the extract, containing less than 8% by weight of epigallocatechin (epigallocatechin, EGC), comprising a green tea extract with reduced hepatotoxicity as an active ingredient, for increasing cerebral blood flow
  • epigallocatechin epigallocatechin, EGC
  • EGC epigallocatechin
  • Green tea extract according to an aspect of the present invention is a low-concentration level that causes hepatotoxicity compared to the existing green tea extract, by effectively changing the components of the green tea extract through high-temperature treatment, it is possible to effectively alleviate hepatocyte damage caused by the existing green tea extract and a large amount High safety even when ingested.
  • composition according to another aspect of the present invention including the green tea extract as an active ingredient, has high safety and excellent blood circulation improvement efficacy, thus exhibiting excellent thrombosis disease prevention or treatment efficacy.
  • composition according to another aspect of the present invention including the green tea extract as an active ingredient, has high safety and has excellent efficacy in inhibiting fat accumulation in liver cells, thereby exhibiting excellent fatty liver prevention or treatment efficacy.
  • composition according to another aspect of the present invention includes the green tea extract as an active ingredient, and exhibits excellent periodontitis prevention or treatment efficacy because it has high safety and excellent inhibitory effect against Porphyromonas gingivalis .
  • composition according to another aspect of the present invention includes the green tea extract as an active ingredient, and exhibits excellent cognitive function improvement efficacy with excellent safety and increased brain blood flow efficiency.
  • Example 1 shows a chromatogram for the general green tea extract of Example 1 (Sample 1).
  • Figure 2 shows a chromatogram for the high-temperature treated green tea extract (sample 2) according to an aspect of the present invention.
  • Figure 3 shows the results of the hepatotoxicity test of the high-temperature treated green tea extract according to Experimental Example 1.
  • Figure 4 shows the results of the experiment confirming the effect on the hepatocyte damage of the high-temperature treated green tea extract according to Experimental Example 2.
  • FIG. 5 shows the results of experiments confirming the effects of three catechins EGCG, GCG and EGC on hepatocyte damage according to Experimental Example 4.
  • Figure 6 shows the results of the experiment to evaluate the blood circulation improvement efficacy of the high-temperature treated green tea extract according to Experimental Example 5.
  • Figure 7 shows the results of the evaluation of the effect of inhibiting fat accumulation in liver cells of the high-temperature treated green tea extract according to Experimental Example 6.
  • Figure 8 shows the results of the experiment of evaluating the efficacy of inhibiting fat accumulation in liver cells of GCG and EGCG according to Experimental Example 7.
  • Figure 9 shows the results of the evaluation of the effect of increasing the blood flow of cerebral blood flow of the high-temperature treated green tea extract according to Experimental Example 9.
  • Figure 10 shows the results of the evaluation of the efficacy of increasing the blood flow of cerebral blood flow of the high-temperature treated green tea extract according to Experimental Example 9.
  • green tea extract is extracted from tea ( Camellia sinensis ), which is an evergreen tree belonging to the family, regardless of the extraction method, extraction solvent, or extracted component or extract type, or Bacillus subtilis spp.), and extracts from fermented tea leaves, etc., and the fractions obtained by fractionation with a specific solvent.
  • the tea includes at least one selected from the group consisting of tea tree leaves, flowers, stems, fruits, roots, stems, and cores of the roots, and may be preferably leaves.
  • the form of the extract may be preferably a powder form.
  • the extraction or fractionation can be performed using water, an organic solvent, or a mixed solvent thereof.
  • the organic solvent may be alcohol, isopropanol, acetone, hexane, ethyl acetate, carbon dioxide, or a mixed solvent of two or more of them, but is not limited thereto, and the active ingredient of green tea is not destroyed or extracted by heating at room temperature or in a minimized condition Or fractionation.
  • the alcohol may be a lower alcohol of C 1 ⁇ C 5 .
  • the number or method of extraction or fractionation is not particularly limited, and for example, methods such as cold immersion extraction, ultrasonic extraction, reflux cooling extraction, and hot water extraction can be used. After filtration, the filtrate is concentrated under reduced pressure to obtain a green tea extract of the present invention.
  • epigallocatechin refers to epigallocatechin (EGC), (-) epicatechin ((-) epicatechin, EC), (-)-epigalocatechin gallate ((-)-epigallocatechin gallate, EGCG), and epicatechin 3-O-gallate (epicatechin-3-O-gallate, ECG).
  • epi-catechin epimer refers to gallocatechin (GC), catechin (C), (-)-gallocatechin gallate (GCG) and catechin gallate (catechin). gallate, CG).
  • the present invention may include an epigallocatechin (EGC) of 8% by weight or less, and may relate to green tea extract with reduced hepatotoxicity.
  • ECC epigallocatechin
  • the present invention to prepare a composition for alleviating liver toxicity, based on the total weight of the extract, comprising less than 8% by weight epigallocatechin (EGC), the use of green tea extract with reduced hepatotoxicity It may be about
  • the present invention may relate to the use of green tea extract with reduced hepatotoxicity, including epigallocatechin (EGC) of 8% by weight or less, based on the total weight of the extract, for alleviating liver toxicity.
  • ECG epigallocatechin
  • the present invention may be related to a composition for improving blood circulation, including the green tea extract as an active ingredient.
  • the composition may be to increase nitrogen monoxide (NO) in vascular endothelial cells, and may exhibit blood circulation improvement effects through increased nitrogen monoxide in vascular endothelial cells.
  • NO nitrogen monoxide
  • the present invention based on the total weight of the extract, comprising the step of administering an effective amount of green tea extract with reduced hepatotoxicity, containing less than 8% by weight epigallocatechin (EGC) It may be related to a method for improving blood circulation, including.
  • the present invention relates to the use of green tea extract with reduced hepatotoxicity, comprising up to 8% by weight of epigallocatechin (EGC), based on the total weight of the extract, for preparing a composition for improving blood circulation.
  • ECG epigallocatechin
  • the present invention may be related to the use of green tea extract with reduced hepatotoxicity, including up to 8% by weight of epigallocatechin (EGC), based on the total weight of the extract, for improving blood circulation.
  • ECG epigallocatechin
  • the present invention may include a composition for inhibiting fat accumulation in liver cells, comprising the green tea extract as an active ingredient.
  • the present invention based on the total weight of the extract, comprising the step of administering an effective amount of green tea extract with reduced hepatotoxicity, containing less than 8% by weight epigallocatechin (EGC) Including, it may be related to a method for inhibiting fat accumulation in liver cells.
  • ECG epigallocatechin
  • the present invention in another aspect, for producing a composition for inhibiting fat accumulation in liver cells, based on the total weight of the extract, containing less than 8% by weight epigallocatechin (EGC), green tea extract with reduced hepatotoxicity It may be related to the use of.
  • ECG epigallocatechin
  • the present invention relates to the use of green tea extract with reduced hepatotoxicity, comprising up to 8% by weight of epigallocatechin (EGC), based on the total weight of the extract, for inhibiting fat accumulation in liver cells.
  • ECG epigallocatechin
  • the present invention may include a green tea extract as an active ingredient, it may be related to a composition for inhibiting ginger ballis.
  • the present invention based on the total weight of the extract, comprising the step of administering an effective amount of green tea extract with reduced hepatotoxicity, containing less than 8% by weight epigallocatechin (EGC) Including, it may be related to a method for inhibiting Ginger Valeris.
  • ECG epigallocatechin
  • the present invention to prepare a composition for inhibiting Ginger Bacillus, based on the total weight of the extract, comprising less than 8% by weight epigallocatechin (EGC), the use of green tea extract with reduced hepatotoxicity It may be about
  • the present invention may be related to the use of green tea extract with reduced hepatotoxicity, including 8% by weight or less of epigallocatechin (EGC), based on the total weight of the extract for inhibiting ginger germ bacteria. have.
  • ECG epigallocatechin
  • the ginger ballis bacteria may be Porphyromonas gingivalis bacteria.
  • the present invention may be related to a composition for increasing cerebral blood flow, comprising the green tea extract as an active ingredient.
  • the composition may be to increase the amount of oxygen in the cerebral blood flow, specifically , May increase blood flow in the frontal lobe portion of the brain.
  • the present invention based on the total weight of the extract, comprising the step of administering an effective amount of green tea extract with reduced hepatotoxicity, containing less than 8% by weight epigallocatechin (EGC) Including, it may be related to a method for increasing cerebral blood flow.
  • ECG epigallocatechin
  • the present invention to prepare a composition for increasing cerebral blood flow, based on the total weight of the extract, comprising less than 8% by weight epigallocatechin (EGC), the use of green tea extract with reduced hepatotoxicity It may be about
  • the present invention may be related to the use of green tea extract with reduced hepatotoxicity, including up to 8% by weight of epigallocatechin (EGC), based on the total weight of the extract, for increasing cerebral blood flow.
  • ECG epigallocatechin
  • administration of the method may be performed according to the administration method and administration dose described herein.
  • the EGC is based on the total weight of the extract 8 wt% or less, 7 wt% or less, 6 wt% or less, 5 wt% or less, 4.7 wt% or less, 4.56 wt% or less, 4.3 wt% or less, 4 It may be less than or equal to 0.3% by weight, less than or equal to 3.53%, less than or equal to 3.5%, less than or equal to 2%, less than or equal to 1%, less than or equal to 0.8%, less than or equal to 0.5%, less than or equal to 0.3% or 0.1% by weight, In another aspect, the EGC is 0.0001% by weight or more, 0.001% by weight or more, 0.01% by weight or more, 1% by weight or more, 2% by weight or more, 3% by weight or more, 3.5% by weight or more, 3.53 based on the total weight of the extract It may be at least 4 wt%, at least 4 wt%, at least 4.3 wt%, at least 4.56
  • the extract is based on the total weight of the extract 4 to 15% by weight of (-)-gallocatechin gallate ((-)-gallocatechin gallate, GCG) and 4 to 15% by weight of (-)-epigal Locatechin gallate ((-)-epigallocatechin gallate, EGCG).
  • the GCG is 4 wt% or more, 5 wt% or more, 5.3 wt% or more, 5.59 wt% or more, 5.7 wt% or more, 6 wt% or more, 7 wt% or more, 8 wt% or more, based on the total weight of the extract, It may be 9% or more, 10% or more, 11% or more, 12% or more, 13% or more, or 14% or more.
  • the GCG is 15% by weight, 14% by weight, 13% by weight, 12% by weight, 11% by weight, 10% by weight, 9% by weight, 8% by weight based on the total weight of the extract %, 7% or less, 6% or less, 5.7% or less, 5.59% or less, 5.3% or less, or 5% or less.
  • the EGCG is based on the total weight of the extract 4 wt% or more, 5 wt% or more, 5.2 wt% or more, 5.27 wt% or more, 5.5 wt% or more, 6 wt% or more, 7 wt% or more, 8 It may be at least 10% by weight, at least 9% by weight, at least 10% by weight, at least 11% by weight, at least 12% by weight, at least 13% by weight, or at least 14% by weight.
  • the EGCG is 15% by weight or less, 14% by weight or less, 13% by weight or less, 12% by weight or less, 11% by weight or less, 10% by weight or less, 9% by weight or less, 8 based on the total weight of the extract It may be less than or equal to 7% by weight, less than or equal to 7%, less than or equal to 5.5%, less than or equal to 5.27%, less than or equal to 5.2%, or less than or equal to 5%.
  • the total content of GCG and EGCG in the extract may be 30% by weight or less based on the total weight of the extract.
  • the total content of the GCG and EGCG is 30 wt% or less, 25 wt% or less, 20 wt% or less, 18 wt% or less, 16 wt% or less, 15 wt% or less, 14 wt% based on the total weight of the extract
  • it may be 12% by weight or less, 11% by weight or less, 10.86% by weight or less, 10% by weight or less, or 9% by weight or less.
  • the total content of the GCG and EGCG is 8% by weight, 10% by weight, 10.86% by weight, 11% by weight, 12% by weight, 13% by weight, 14% by weight based on the total weight of the extract % Or more, 16% or more, 18% or more, 20% or more, or 25% or more.
  • the epicatechin content in the extract may be 20% by weight or less based on the total weight of the extract.
  • the epicatechin content is 20 wt% or less, 18 wt% or less, 16 wt% or less, 15 wt% or less, 14 wt% or less, 12 wt% or less, 11.1 wt% or less based on the total weight of the extract, or It may be 10% by weight or less.
  • the epicatechin content is at least 9% by weight, at least 10% by weight, at least 11.1% by weight, at least 12% by weight, at least 13% by weight, at least 14% by weight, at least 16% by weight based on the total weight of the extract, or It may be 18% by weight or more.
  • the total content of 8 catechins in the extract i.e., (-)-epigallocatechin gallate (EGCG), epigallocatechin (EGC) in the extract (-) Epicatechin ((-) epicatechin (EC)), epicatechin 3-O-gallate (ECG), gallocatechin gallate (GCG), gallocatechin (GC),
  • the total content of catechin (C) and catechin gallate (CG) may be 19 to 30% by weight based on the total weight of the extract.
  • the total content of the eight catechins is 19% by weight or more, 21% by weight or more, 23% by weight or more, 24% by weight or more, 24.5% by weight or more, 25% by weight or more, 26% by weight based on the total weight of the extract % Or more, 27% or more, 28% or more, or 29% or more.
  • the total content of the eight catechins is 30% by weight or less, 29% by weight or less, 28% by weight or less, 27% by weight or less, 26% by weight or less, 25% by weight or less, 24.5% by weight based on the total weight of the extract % Or less, 24% or less, 23% or less, or 21% or less.
  • the extract may be an extract extracted one or more times by any one or more of water and C1 to C4 alcohol.
  • the alcohol may be ethanol.
  • the alcohol may be 20% or more, 30% or more, 40% or more, 50% or more, 60% or more, or 70% or more ethanol.
  • the alcohol may be 70% or less, 60% or less, 50% or less, 40% or less, or 30% or less ethanol.
  • the extract may be contained in a dietary supplement or pharmaceutical composition.
  • the content of the green tea extract in the dietary supplement or pharmaceutical composition may be 1% to 100% by weight relative to the total weight of the composition.
  • the content of the extract in the composition is 1 wt% or more, 10 wt% or more, 20 wt% or more, 30 wt% or more, 40 wt% or more, 50 wt% or more, 60 wt% or more, 70 wt% Or more, 80% or more, or 90% or more.
  • the content of the extract in the composition is 100% or less, 90% or less, 80% or less, 70% or less, 60% or less, 50% or less, 40% or less, 30% or less Or less or 20% by weight.
  • the dosage of the green tea extract may be 5 mg / kg / day to 1000 mg / kg / day.
  • the dosage is 5 mg / kg / day or more, 100 mg / kg / day or more, 200 mg / kg / day or more, 300 mg / kg / day or more, 400 mg / kg / day or more, 500 mg / kg / day or more, It may be 600 mg / kg / day or more, 700 mg / kg / day or more, 800 mg / kg / day or more, or 900 mg / kg / day or more.
  • the dosage is 1000 mg / kg / day or less, 900 mg / kg / day or less, 800 mg / kg / day or less, 700 mg / kg / day or less, 600 mg / kg / day or less, 500 mg / kg / day or less, It may be 400 mg / kg / day or less, 300 mg / kg / day or less, 200 mg / kg / day or less, 100 mg / kg / day or less, 50 mg / kg / day or less, or 10 mg / kg / day or less.
  • the formulation of the food composition is not particularly limited, for example, tablets, granules, pills, powders, liquids such as drinks, caramels, gels, bars, tea bags, etc. may be formulated.
  • the food composition of each formulation can be formulated by appropriately selecting the ingredients commonly used in the field other than the active ingredient according to the formulation or purpose of use without difficulty, and synergistic effect when applied simultaneously with other ingredients. Can happen.
  • the food may be a health functional food.
  • composition may be administered by various methods such as simple ingestion, drinking, injection, spray administration, or squeeze administration.
  • the dosage of the active ingredient is within the level of those skilled in the art, and may vary depending on various factors such as age, health condition, and complications of the subject to be administered. .
  • Food composition for example, chewing gum, caramel products, candy, ice cream, confectionery, various foods, soft drinks, mineral water, alcoholic beverages, beverage products, vitamins and minerals, etc. It may be a functional food product.
  • the food composition according to one aspect of the present invention includes various nutrients, vitamins, minerals (electrolytes), flavoring agents such as synthetic flavoring agents and natural flavoring agents, colorants and enhancers (cheese, chocolate, etc.), pectic acid and the like. Salts, alginic acid and salts thereof, organic acids, protective colloidal thickeners, pH adjusting agents, stabilizers, preservatives, glycerin, alcohols, carbonic acid used in carbonated beverages, and the like.
  • food compositions according to one aspect of the present invention may include natural fruit juice and fruit juice for the production of fruit juice drinks and vegetable drinks. These ingredients can be used independently or in combination. The proportion of these additives is not so critical, but is generally included in the range of 0 to about 60 parts by weight per 100 parts by weight of the composition according to one aspect of the present invention.
  • the food composition according to an aspect of the present invention may be that the liver toxicity of green tea extract is alleviated. More specifically, the food composition may be that the liver toxicity by EGC in green tea extract is alleviated.
  • compositions according to an aspect of the present invention may be administered orally, parenteral, rectal, topical, transdermal, intravenous, intramuscular, intraperitoneal, subcutaneous, and the like.
  • Formulations for oral administration may be tablets, pills, soft and hard capsules, granules, powders, granules, liquids, emulsions or pellets, but are not limited thereto. It is not.
  • Formulations for parenteral administration may be solutions, suspensions, emulsions, gels, injections, drops, suppositories, patches or sprays, but are not limited thereto.
  • formulations can be readily prepared according to conventional methods in the art, surfactants, excipients, hydrating agents, emulsifying accelerators, suspending agents, salts or buffers for controlling osmotic pressure, colorants, spices, stabilizers, preservatives, preservatives or Other commercial adjuvants may be further included.
  • the pharmaceutical composition according to an aspect of the present invention may include a pharmaceutically acceptable salt, wherein the salt is formed of an inorganic acid such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, etc .; Or acetic acid, propionic acid, hexanoic acid, cyclopentanepropionic acid, glycolic acid, pyruvic acid, lactic acid, malonic acid, succinic acid, malic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, 3- (4-hydroxybenzoyl) Benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, 1,2-ethane-disulfonic acid, 2-hydroxyethanesulfonic acid, benzenesulfonic acid, 4-chlorobenzenesulfonic acid, 2-naphthalenesulfonic acid, 4-Tolu
  • the applied amount or dosage of the pharmaceutical composition according to an aspect of the present invention will vary depending on the age, gender, weight, pathology and severity of the subject to be administered, the route of administration or the judgment of the prescriber.
  • the determination of the active ingredient dosage based on these factors is within the level of those skilled in the art.
  • composition analysis conditions of Samples 1 and 2 composition analysis conditions of Samples 1 and 2
  • Table 2 composition analysis results of Sample 1
  • Table 3 composition analysis results of Sample 2
  • chromatograms for the two types of extracts are shown in Fig. 1 (sample 1) and 2 (sample 2). That is, it was confirmed that the composition of Sample 2 is different from the existing green tea extract.
  • Sample 2 contains significantly lower EGC (3.53% by weight), EGCG (5.27% by weight), and total catechin (24.41% by weight) than Sample 1, whereas Sample 1 has four components that are not found. It was confirmed that the epicatechin epimer of was additionally produced.
  • GC gallocatechin
  • EGC epigallocatechin
  • C catechin
  • EC (-) epicatechin
  • GCG gallocatechin gallate
  • EGCG epigallocatechin gallate
  • CG Catechin gallate
  • ECG epicatechin 3-O-gallate
  • Example 2 the hepatocyte cell line (HepG2 cell line) obtained from the Korean Cell Line Bank was placed in a 96 well plate (well plate, FALCON) 1X10 5 per well. After seeding each time, and cultured in a 37 ° C, 5% CO 2 incubator for 24 hours, the samples 1 and 2 were treated with 5, 10, 25, 50, 100 ⁇ g / ml, respectively, and further cultured for 24 hours. After removing the medium, cell viability was confirmed using a CellTiter 96 AQueous One Solution Cell Proliferation Assay Kit (MTS, Promega Co. Madison, WI, USA).
  • MTS CellTiter 96 AQueous One Solution Cell Proliferation Assay Kit
  • Cell viability (%) (Absorbance of the sample treated group-Absorbance of only the reaction reagent) / (Absorbance of the untreated group-Absorbance of the reaction reagent only) X 100
  • the sample 2 according to the present invention has low hepatocellular toxicity compared to the sample 1, which is a normal green tea extract.
  • Example 2 In order to confirm the effect of the high-temperature-treated green tea extract (Sample 2) obtained in Example 1 on liver cell damage, an analysis program (MILLIPLEX Analyst, Millipore) was used to analyze the degree of hepatocellular enzyme outflow due to hepatocyte damage. Analysis. Experimental conditions are the same as in Experimental Example 1, and after treatment of Sample 1 and Sample 2, the level of MDH 1 (malate dehydrogenase 1), GST ⁇ ( ⁇ -glutathione S-transferase), and SDH (sorbitol dehydrogenase) in the cell culture solution was 24 hours. It was measured.
  • MDH 1 malate dehydrogenase 1
  • GST ⁇ ⁇ -glutathione S-transferase
  • SDH sorbitol dehydrogenase
  • hepatocyte cell line obtained from the Korea Cell Line Bank
  • hepatocyte cell line obtained from the Korea Cell Line Bank
  • EGC has the highest effect on hepatocyte damage compared to EGCG and GCG.
  • Endothelial nitric oxide synthase is present in human vascular endothelial cells, and its activity is increased to produce nitrogen monoxide (NO) to expand blood vessels and promote blood circulation.
  • NO nitrogen monoxide
  • vascular endothelial cells were seeded at 2X10 4 per well in a 96-well plate (clear-plate, black, well plate, FALCON) with a transparent bottom and a black wall, and seeded for 24 hours at 37 ° C and 5% CO 2 After incubation in an incubator, cells were starvated for 4 hours with phenol red free medium from which fetal bovine serum (FBS) was removed, and then the medium was removed and washed twice with PBS (phosphate buffer saline).
  • FBS fetal bovine serum
  • DAF-2DA was dissolved in HBSS (Hank's Balanced Salt Solution) with 5 ⁇ M, treated with 100 ⁇ l of cells, and then incubated in a 5% CO 2 incubator for 20 minutes by blocking the light with foil. Fluorescence was measured before sample treatment (excitation: 485 nM, emission: 535 nM), and sample 1 and sample 2 were prepared at 6, 20, and 60 ⁇ g / ml, respectively, and treated with 100 ⁇ l in each well, followed by microplate reader ( Fluorescence is measured with Tecan Salzburg, Austria). Meanwhile, instead of samples 1 and 2, DMSO (dimethylsulfoxide) was treated with 0.1% (v / v) as a control. The relative NO production was calculated by the following equation.
  • Relative NO production (absorbance of sample treatment group-absorbance of reaction reagent only) / (absorbance of control group (DMSO treatment group)-absorbance of reaction reagent only)
  • the high-temperature-treated green tea extract according to the present invention has high hepatotoxicity and low safety compared to the conventional green tea extract, but also contains a large amount of NO in a smaller amount in vascular endothelial cells. It can be seen that it exhibits excellent blood circulation improvement efficacy.
  • the hepatocyte cell line (HepG2 cell line) is seeded in a 12-well plate (well plate, FALCON) for 1 ⁇ 10 6 per well, and cultured in a 37 ° C., 5% CO 2 incubator for 24 hours, and then the sample 1 And sample 2 were treated with 3, 10, 30 ⁇ g / ml and bovine serum albumin (BSA) and conjugated stearic acid 100 ⁇ M, respectively, and cultured for 48 hours. The medium was removed, washed with PBS, and fixed with 4% formaldehyde.
  • BSA bovine serum albumin
  • Amount of oil red O (%) (absorbance of sample treatment group-control absorbance) X 100
  • the high-temperature-treated green tea extract according to the present invention has low liver toxicity compared to the conventional green tea extract, has high safety, and has excellent remarkable ability to inhibit fat accumulation in liver cells, and has excellent fatty liver prevention efficacy. It can be seen that indicates.
  • the results are as shown in FIG. 8, and it was confirmed that GCG has a significantly superior inhibitory effect on fat accumulation in liver cells compared to EGCG at the same concentration. Accordingly, it was found that the high-temperature-treated green tea extract according to the present invention has a much lower EGCG content than the normal green tea extract and contains GCG components not found in the general green tea extract, thereby showing excellent ability to inhibit fat accumulation in liver cells.
  • samples were prepared by mixing the ingredients and composition ratios shown in Table 5 below. Each sample was prepared in stock 100 times the corresponding content and used for the experiment, and the content of each component in Sample 2 is the same as the content of 8 kinds of catechins in Table 3.
  • the high-temperature-treated green tea extract according to the present invention has low liver toxicity compared to the conventional green tea extract, has high safety, and has excellent efficacy in inhibiting Gingervalis bacteria, and has excellent periodontitis prevention efficacy. It can be seen that indicates.
  • NIRS Near infrared spectroscopy
  • NIRSIT functional near infrared spectroscopy
  • the high-temperature-treated green tea extract according to the present invention has low hepatotoxicity compared to the conventional green tea extract, and has high safety while increasing the blood flow in the frontal lobe of the brain, thereby improving the cognitive function. It shows that it shows.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Medical Informatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

La présente invention concerne un extrait de thé vert ayant une teneur en constituants modifiée, qui présente une hépatotoxicité réduite, et une composition le comprenant en tant que principe actif pour améliorer la circulation sanguine, inhiber l'accumulation de lipides dans les hépatocytes, inhiber le développement de bactéries gingivalis, ou augmenter le débit sanguin cérébral. Spécifiquement, un aspect de la présente invention concerne un extrait de thé vert comprenant des constituants qui sont modifiés par traitement à une température élevée pour ainsi avoir une concentration plus faible de celui qui provoque une hépatotoxicité par rapport à des extraits de thé vert classiques, ce qui permet de réduire les dommages subis par les hépatocytes. La composition comprenant un tel extrait de thé vert selon la présente invention présente une innocuité élevée, même lorsqu'elle est ingérée en grandes quantités, et présente une excellente efficacité dans l'amélioration de la circulation sanguine, l'inhibition de l'accumulation de lipides dans les hépatocytes, l'inhibition du développement de bactéries gingivalis, ou l'augmentation du débit sanguin cérébral.
PCT/KR2019/014810 2018-11-05 2019-11-04 Extrait de thé vert ayant une teneur en constituants modifiée et composition le comprenant WO2020096299A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN201980073102.7A CN112996526B (zh) 2018-11-05 2019-11-04 成分含量变化的绿茶提取物及包含其的组合物
EP19881736.3A EP3878460A4 (fr) 2018-11-05 2019-11-04 Extrait de thé vert ayant une teneur en constituants modifiée et composition le comprenant

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
KR20180134620 2018-11-05
KR10-2018-0134620 2018-11-05
KR1020190037810A KR20200051452A (ko) 2018-11-05 2019-04-01 성분 함량이 변화된 녹차 추출물
KR10-2019-0037810 2019-04-01
KR10-2019-0129034 2019-10-17
KR1020190129034A KR20200051480A (ko) 2018-11-05 2019-10-17 성분 함량이 변화된 녹차 추출물, 및 이를 포함하는 조성물

Publications (1)

Publication Number Publication Date
WO2020096299A1 true WO2020096299A1 (fr) 2020-05-14

Family

ID=70611396

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2019/014810 WO2020096299A1 (fr) 2018-11-05 2019-11-04 Extrait de thé vert ayant une teneur en constituants modifiée et composition le comprenant

Country Status (1)

Country Link
WO (1) WO2020096299A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3126870A1 (fr) * 2021-09-16 2023-03-17 Gozen K. K. Japan Composition pharmaceutique ou cosmétique destinée à améliorer la cellulite et les varices caractérisée en ce qu’elle comprend une association de théanine et des polysaccharides issus du matcha.

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20030009578A (ko) * 2001-07-03 2003-02-05 주식회사 태평양 구취억제용 구강용 조성물
KR20050022250A (ko) * 2003-08-30 2005-03-07 삼아약품 주식회사 녹차카테킨을 유효성분으로 포함하는 간 기능 개선제
KR20100124519A (ko) * 2009-05-19 2010-11-29 (주)아모레퍼시픽 녹차 추출물을 함유하는 조성물
KR20150016343A (ko) * 2012-05-21 2015-02-11 디에스엠 뉴트리셔널 프라덕츠 아게 식료품 첨가제의 안정성을 증가시키기 위한 조성물 및 방법
WO2015199169A1 (fr) * 2014-06-27 2015-12-30 国立大学法人九州大学 Procédé d'amélioration de la fonction de la catéchine

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20030009578A (ko) * 2001-07-03 2003-02-05 주식회사 태평양 구취억제용 구강용 조성물
KR20050022250A (ko) * 2003-08-30 2005-03-07 삼아약품 주식회사 녹차카테킨을 유효성분으로 포함하는 간 기능 개선제
KR20100124519A (ko) * 2009-05-19 2010-11-29 (주)아모레퍼시픽 녹차 추출물을 함유하는 조성물
KR20150016343A (ko) * 2012-05-21 2015-02-11 디에스엠 뉴트리셔널 프라덕츠 아게 식료품 첨가제의 안정성을 증가시키기 위한 조성물 및 방법
WO2015199169A1 (fr) * 2014-06-27 2015-12-30 国立大学法人九州大学 Procédé d'amélioration de la fonction de la catéchine

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KIM, MIN CHAE ET AL.: "Robust optimization for the simultaneous enhancement of nitric oxide inhibition and reduction of hepatotoxicity from green tea catechins", FOOD SCIENCE AND BIOTECHNOLOGY, vol. 26, no. 6, 14 July 2017 (2017-07-14), pages 1725 - 1734, XP036400782, ISSN: 1226-7708, DOI: 10.1007/s10068-017-0111-5 *
ZHAO, L. ET AL: "Antibacterial, antiadherence, antiprotease, and ami-inflammatory activities of various tea extracts: potential benefits for periodontal diseases", JOURNAL OF MEDICINAL FOOD, vol. 16, no. 5, 15 May 2013 (2013-05-15), pages 428 - 436, XP055705594, ISSN: 1096-620X, DOI: 10.1089/jmf.2012.0207 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3126870A1 (fr) * 2021-09-16 2023-03-17 Gozen K. K. Japan Composition pharmaceutique ou cosmétique destinée à améliorer la cellulite et les varices caractérisée en ce qu’elle comprend une association de théanine et des polysaccharides issus du matcha.

Similar Documents

Publication Publication Date Title
WO2014084572A1 (fr) Agent améliorant la biodisponibilité de la catéchine comprenant de la cyclodextrine
KR101938864B1 (ko) 항산화 및 피부 개선용 조성물
WO2015002391A1 (fr) Composition présentant une fonction d'atténuation du syndrome prémenstruel et des douleurs menstruelles
KR20240078638A (ko) 성분 함량이 변화된 녹차 추출물을 포함하는 산화스트레스로부터 세포를 보호하기 위한 조성물
KR20190002105A (ko) 땅콩 새싹 추출물 또는 이의 분획물을 포함하는 대사성 질환의 예방 또는 치료용 조성물
KR20200051480A (ko) 성분 함량이 변화된 녹차 추출물, 및 이를 포함하는 조성물
WO2020096299A1 (fr) Extrait de thé vert ayant une teneur en constituants modifiée et composition le comprenant
WO2016190566A9 (fr) Composition pharmaceutique ou aliment naturel fonctionnel pour la prévention et le traitement de maladies métaboliques, contenant un extrait aqueux de pleurotus eryngii var. ferulae (pf.) en tant que principe actif
WO2019088482A1 (fr) Composition pour améliorer des maladies du système circulatoire, comprenant un extrait de thé ayant un contenu d'ingrédients varié
WO2018230906A1 (fr) Composition de blanchiment contenant un nouveau composé à base de quercétine
WO2016117762A1 (fr) Composition contenant un extrait de groseille à maquereau ou du glutathion
KR102465484B1 (ko) 엔테로코커스 패칼리스 사균체를 유효성분으로 함유하는 비만 또는 비만으로부터 유도된 대사증후군의 예방 또는 치료용 조성물
WO2018230909A1 (fr) Composition anti-inflammatoire comprenant un nouveau composé à base de kaempférol dérivé de thé post-fermenté
KR102418100B1 (ko) 신규한 퀘르세틴계 화합물을 포함하는 인지기능 개선용 조성물
WO2018190638A1 (fr) Composition pour la prévention ou le traitement de maladies cornéennes, contenant un extrait de glycine max
WO2018230908A1 (fr) Composition anti-inflammatoire comprenant un nouveau composé à base de quercétine
WO2023287001A1 (fr) Composition pour le traitement ou l'amélioration d'une maladie hépatique et d'un dysfonctionnement hépatique comprenant un extrait de zizania latifolia
WO2018074791A1 (fr) Composition améliorant la fonction cognitive comportant un nouveau composé à base de quercétine
WO2018074793A1 (fr) Composition améliorant la fonction cognitive comprenant un nouveau composé à base de kaempférol dérivé du thé post-fermenté
WO2018016826A1 (fr) Composition contenant du 3-o-galloyl-3,3',5,5',7-pentahydroxyflavane pour améliorer la fonction cognitive
WO2022114470A1 (fr) Composition comprenant une fraction d'un extrait de syzygium formosum en tant que principe actif
WO2020218755A1 (fr) Composition permettant de favoriser la différenciation adipocytaire comprenant de la théaflavine
WO2018230910A1 (fr) Composition de blanchiment comprenant un nouveau composé à base de kaempférol dérivé de thé post-fermenté
KR102394643B1 (ko) 후발효차 유래의 신규한 캄페롤계 화합물을 포함하는 인지기능 개선용 조성물
WO2015108332A1 (fr) Composition pour prévenir et traiter une maladie cardiovasculaire

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19881736

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2019881736

Country of ref document: EP

Effective date: 20210607